Alladapt Immunotherapeutics

Developing prescription therapeutics to address #foodallergy.
Follow/like/RT≠endorsement

[Alladapt Immunotherapeutics @AlladaptImmuno]

Thank you @GoHealio for the opportunity to discuss how ADP101 addresses limitations in #FoodAllergy OIT treatments and our recently presented Phase 1/2 Harmony data at #ACAAI23.

Read the interview with our CEO @ashdombkowski below. https://t.co/3YsQ9DzSBg

[Alladapt Immunotherapeutics @AlladaptImmuno]

Our CEO @ashdombkowski recently spoke with @abi_beaney at @TrialsArena about ADP101, our innovative investigational oral immunotherapy which covers 9 key #foodallergen groups.

Learn more below. https://t.co/i7G5xEN55R

#FoodAllergies #ClinicalData

[Alladapt Immunotherapeutics @AlladaptImmuno]

Happy #Thanksgiving from our Alladapt family to yours!

[Alladapt Immunotherapeutics @AlladaptImmuno]

Let's make this #Thanksgiving inclusive for everyone! Don't forget to ask your guests about #FoodAllergies to help ensure that everyone can safely enjoy a delicious meal.

Check out more tips for accommodating allergies when you're holiday hosting: https://t.co/3Clu56Ux7I

[Alladapt Immunotherapeutics @AlladaptImmuno]

ADP101 has received Fast Track designation from the FDA, marking an important milestone for people suffering from #FoodAllergy. We'll continue to work closely with the FDA to expedite development of this important therapy.

Learn more in our press release: https://t.co/eZt8spOFOZ

[Alladapt Immunotherapeutics @AlladaptImmuno]

We're grateful for the opportunity to share promising results with the food allergy community at #ACAAI23! #ICYMI, read highlights from our Phase 1/2 Harmony Study evaluating ADP101 for the treatment of patients with mono- and multi- #FoodAllergy here: https://t.co/tSfQ0GoTTg

[Alladapt Immunotherapeutics @AlladaptImmuno]

Tomorrow at #ACAAI23, we will present data from our Phase 1/2 Harmony study demonstrating the therapeutic potential and safety of ADP101 for the treatment of #FoodAllergy.

Learn more in today's press release and join us @ACAAI tomorrow: https://t.co/tSfQ0Gom3I

[Alladapt Immunotherapeutics @AlladaptImmuno]

We're presenting at the #ACAAI23 Annual Scientific Meeting next week and look forward to connecting with the #FoodAllergy community in Anaheim.

Register at https://t.co/0btTnd9ZJz and join us @ACAAI!

[Alladapt Immunotherapeutics @AlladaptImmuno]

Happy Halloween from Alladapt!

[Alladapt Immunotherapeutics @AlladaptImmuno]

#DYK 1 in 13 children are living with #FoodAllergies? Place a teal pumpkin on your doorstep to let trick-or-treaters know that you offer non-food treats that are safe for everyone.

Learn more about the #TealPumpkinProject: https://t.co/2HNCTXzuLo @FoodAllergy #HappyHalloween

[Alladapt Immunotherapeutics @AlladaptImmuno]

Our CEO @ashdombkowski will be speaking alongside other life science leaders this Friday at the @biocom CEO Summit.

We look forward to connecting with our peers and discussing Alladapt's mission to help people with #FoodAllergies worldwide. #BiocomCEOSummit

[Alladapt Immunotherapeutics @AlladaptImmuno]

Members of our Clinical team attended the FARE Food Allergy Summit to meet with our Patient Advisory Council (PAC). We learned about PAC members' burden of disease and discussed benefits of OIT treatment. Their invaluable input will help inform our Phase 3 program. @FoodAllergy

[Alladapt Immunotherapeutics @AlladaptImmuno]

According to @CDCgov, #foodallergies doubled among children between 2000 and 2018. Data supports that this trend also applies to adults, underscoring the need for effective treatments to address this troubling increase.

Read more: https://t.co/f1deRzpOWb

[Alladapt Immunotherapeutics @AlladaptImmuno]

There are more college students living with food allergies each year. While higher ed is doing its part with allergen-free meal plans and dining halls, effective treatments are required to fully meet these students' critical needs. We're working on it!
https://t.co/wglkxSdrff

[Alladapt Immunotherapeutics @AlladaptImmuno]

It was great to reconnect as a team in Half Moon Bay last week! We're fortunate to have a tight community of passionate scientists and professionals and are feeling energized going into the last few months of the year.

[Alladapt Immunotherapeutics @AlladaptImmuno]

Members of our team recently attended the 16th International Paul Ehrlich Seminar (IPES), a leading expert forum for the discussion of regulation, science and future of diagnostics and treatments for allergic diseases including food allergy. @PEI_Germany #IPES2023

[Alladapt Immunotherapeutics @AlladaptImmuno]

Today, we're participating in the I&I panel at @Citi’s #BioPharma Conference in Boston. Food allergy affects 32m in the US alone; 95% lack treatments. Rapid clinical advances in #immunology are poised to change this. View the webcast: https://t.co/ZRcc0xLsND

[Alladapt Immunotherapeutics @AlladaptImmuno]

#Didyouknow that people can develop a food allergy at any age? Many adults develop food allergies even without a prior history of a childhood allergy diagnosis, and as many as 32 million Americans are affected.
https://t.co/n3zz1jniHX

[Alladapt Immunotherapeutics @AlladaptImmuno]

We are constantly working on providing the best resources for #allergyadvocacy to the patient community – helping our patients is at the core of everything we do.

https://t.co/UI3VXHr9V1

[Alladapt Immunotherapeutics @AlladaptImmuno]

Alladapt is committed to keeping patients safe with #foodallergies education & awareness, as we strive to support food allergy advocacy. Check out some food allergy basics from @FAACT here: https://t.co/CxkcK2yjGh